Nephrogen Biotech
Company Type: Therapeutic development
Main focus: Developing gene therapies to treat kidney disease
Company stage: Pre-clinical
Diseases: Autosomal dominant polycystic kidney disease (ADPKD) and other kidney diseases
Genome-editing tool: CRISPR-Cas9
Funding stage: Non-equity Assistance
Location: New York, New York, USA
Website: www.nephrogenbiotech.com
Pipeline:
Partners:
Nephrogen is a pre-clinical biotech company developing curative gene therapies for kidney diseases, with a primary focus on autosomal dominant polycystic kidney disease (ADPKD). The company's platform combines CRISPR-Cas genome-editing technology with advanced nucleic acid delivery systems, including adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs), to target kidney diseases at their genetic source. Nephrogen aims to address a significant unmet medical need, as ADPKD affects approximately 600,000 Americans and currently lacks effective treatment options. The company has established a broad patent portfolio to support its therapeutic development and future partnerships in the kidney disease space.